Clinical efficacy of current therapies for hepatocellular carcinoma (HCC) treatment is limited. Indole-3-acetic acid (IAA) is non-toxic for mammalian cells. Oxidative decarboxylation of IAA by horseradish peroxidase (HRP) leads to toxic effects of IAA. The purpose of this study was to investigate the effects of a novel gene-targeted enzyme prodrug therapy with IAA on hepatoma growth in vitro and in vivo mouse hepatoma models. We generated a plasmid using adenovirus to express HRP isoenzyme C (HRPC) with the HCC marker, alpha-fetoprotein (AFP), as the promoter (pAdv-AFP-HRPC). Hepatocellular cells were infected with pAdv-AFP-HRPC and treated with IAA. Cell death was detected using MTT assay. Hepatoma xenografts were developed in mice by injection of mouse hepatoma cells. The size and weight of tumors and organs were evaluated. Cell death in tumors was assessed using hematoxylin and eosin-stained tissue sections. HRPC expression in tissues was detected using Reverse Transcriptase-Polymerase Chain Reaction. IAA stimulated death of hepatocellular cells infected with pAdv-AFP-HRPC, in a dose-and time-dependent manner, but not in control cells. Growth of hepatoma xenografts, including the size and weight, was inhibited in mice treated with pAdv-AFP-HRPC and IAA, compared with that in control group. pAdv-AFP-HRPC/IAA treatment induced cell death in hepatoma xenografts in mice. HRPC gene expressed only in hepatoma, but not in other normal organs of mice. pAdv-AFP-HRPC/IAA treatment did not cause any side effects on normal organs. These findings suggest that pAdv-AFP-HRPC/IAA enzyme/prodrug system may serve as a strategy for HCC therapy.
Introduction
Hepatocellular carcinoma (HCC), a highly prevalent malignancy, is the third leading cause of cancer-related deaths in the world. [1] [2] [3] [4] Several risk factors have been identified to mediate HCC tumorigenesis, including chronic infection with hepatitis B virus and hepatitis C virus, toxicity, and dysregulation of metabolic and immune responses. 5 Multiple molecular mechanisms regulating pathogenesis of HCC have been found, such as tissue damage-induced cirrhosis with hepatic regeneration and mutations in single or multiple oncogenes or tumor-suppressor genes. 6 Although many research efforts have been applied for improving the diagnosis and treatment of HCC, clinical efficacy of traditional therapies for HCC is limited. 3, 4, 7 For example, surgical resection provides a significant survival advantage for patients with early stage of HCC, however, many patients are diagnosed in the late stage and cannot tolerate hepatectomy because of poor liver function reserve. 8 Therefore, there is a need to develop new strategies to treat HCC.
Tumor-targeted gene therapy, an attractive strategy of disease treatment, was first applied for clinical trial in 1990. 9, 10 As of now, more than 400 gene therapy clinical trials have been performed worldwide. More than half of these clinical trials were performed for investigating cancer treatment. One of the major goals for improving tumor therapy is to specifically deliver toxic agents to tumor cells. Gene-directed enzyme prodrug delivery approach has been shown as a promising strategy of tumor-targeted gene therapy. 11 Recent studies have shown that indole-3-acetic acid (IAA), a plant hormone, may serve as a new cancer therapeutic agent through oxidative decarboxylation by horseradish peroxidase (HRP). [12] [13] [14] IAA is well tolerated in humans and is not oxidized by mammalian peroxidases. 15 Horseradish peroxidase isozyme C (HRPC) oxidizes IAA to produce free radicals that are cytotoxic to mammalian cells. [16] [17] [18] [19] IAA or HRP alone shows no cytotoxic effect in mammalian cells. Only the combination of these two compounds can result in cell death. [16] [17] [18] [19] One strategy to selectively induce tumor cell death and avoid damage to normal tissues is to target HRP on tumor cells for producing the toxic IAA metabolites. As the high level of alpha-fetoprotein (AFP) is expressed in liver tumor cells, but not in adult normal liver cells, 20, 21 AFP has been chosen as a promoter for liver tumor-targeted gene delivery. In this study, we developed a novel adenovirus (Adv)-mediated prodrug system containing AFP promoter, HRPC and IAA (Adv-AFP-HRPC/IAA). We investigated the effects and safety of this system on three human tumor cell lines in vitro and on growth of hepatoma xenografts in BALB/C mice. We found that the Adv-AFP-HRPC/IAA system promoted tumor cell death in vitro and suppressed growth of hepatoma xenografts in mice. Thus, targeted gene therapy using Adv-AFP-HRPC/IAA system may serve as an attractive strategy for treatment of liver tumors.
Materials and methods

Cell culture
Hep-3B, Hep-G2, Huh7 and mouse hepatoma cell line H22 were obtained from Chinese Center of Typical Culture Conserve, Wuhan, China. 293T cells were provided by Dr Jiajie Hu (School of Life Science, Wuhan University, Wuhan, China). Hep-3B, Hep-G2, Huh7 and 293Tcells were grown in Dulbecco's minimal essential medium with 2 mM L-glutamine, 10% fetal bovine serum, 50 mg ml À1 penicillin, 100 mg ml À1 streptomycin in a humidified incubator at 37 1C and 5% CO 2 /air. H22 cell was maintained by transplantation into the abdominal cavity of BALB/C mice. Cells were isolated from cancerous ascites and washed with phosphate-buffered saline, counted with cell viability analyzer (Vi-CELL, Beckman-Coulter Limited, Fullerton, CA, USA) before transplantation into mice.
Plasmid pAdv-AFP-HRPC construction and cell transfection The adenoviral vector system, including donor plasmid pRTRA and recipient plasmid, was provided by Professor Lixin Ma (Institute of Biochemistry and Molecular Biology, Hubei University, Wuhan, China). The 294-bp AFP promoter was amplified by polymerase chain reaction (PCR) using 5 0 -GCAGATCTATTCTGTA GTTTGAGGAG-3 0 and 5 0 -ATCCTCAGGATTGGCAG TGGTGGAA-3 0 as the primers. The AFP gene fragment was cloned into pRTRA and replaced the CMV gene to create pRTRA-AFP plasmid. HRPC gene was amplified by PCR using the primers 5 0 -ATGCTTCATGCATCTTT TTCC-3 0 and 5 0 -TCACATAGAGCTAACAAAGTC-3 0 and subcloned into donor plasmid pRTRA-AFP. The integrity of the HRPC gene constructs was confirmed by DNA sequencing analysis. The recombinant plasmid (pAdv-AFP-HRPC) was constructed using mating-assisted genetically integrated cloning methods, as described before, 22, 23 and then transfected into 293T cells to produce infectious recombinant adenovirus (Adv-AFP-HRPC). Viral particle number was calculated by detecting the absorbance at 260 nm (A 260 ). One absorbency unit was equivalent to 1 Â 10 12 viral particle per ml. The total number of plaque-forming units (PFU) was determined by titration on 293T cell. These infectious titers were used to be multiplicity of infection.
MTT assay Cells in 96-well plates were infected with Adv-AFP-HRPC at multiplicity of infection of 0.2. After cells were treated with IAA, the cell number was measured using MTT assay, following manufacturer's instruction. The percentage of cell death was calculated as: 100%À(the average absorbency of experimental group/the average absorbency of control group Â 100%).
Mice and treatment
All animal experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee of Wuhan University. Male BALB/C (6-week-old) were obtained from Laboratory Animal Center of Hubei Academy of Preventive Medicine (Wuhan, China). H22 cells were harvested and then diluted with physiological concentration of saline to 5 Â 10 6 cells ml
À1
. A total of 0.2 ml of H22 cell suspension (5 Â 10 6 cells ml
) was inoculated subcutaneously in the right flank of mice. All animals were given 0.5 ml of 1.0 mg ml À1 IAA at day 10 of post inoculation by intragastric administration once a day, until mice were killed. When the xenograft reached 8 mm in diameter after 2 weeks following transplantation, mice were divided into five groups (30 mice per group): three groups were injected with 10 5 , 10 4 , 10 3 pfu Adv-AFP-HRPC, respectively. One group was injected with adriamycin (ADM), and the other one was given vehicle (supernatant of noninfected 293T cells) as a negative control. All mice were injected once a week for 2 weeks, and killed a week after the fourth injection. The tumors were measured in two dimensions with external calipers every 2 days. The tumor volume was calculated as length Â width 2 Â 0.4.
Blood biochemical and hematological examination
Before killing the mice, blood was collected for blood biochemical and hematological assays using biochemical auto-analyzer (Hitachi 7080, Hitachi High Tech, Yokohama, Japan) and automated hematology analyzer (Cell-DYN 1800, Abbott, Alameda, CA, USA), respectively. A statistical analysis was performed using the Student's t-test.
Tissue preparation and examination
The tumor, heart, liver, spleen, lungs and kidneys were removed and weighed. Tissue samples were fixed in 10% formalin and embedded in paraffin blocks. Tissue sections were stained using hematoxylin-eosin for light microscopic examination.
RT-PCR analysis
Total RNA was extracted from tissues using the Trizol reagent (Invitrogen, Carlsbad, CA, USA), following manufacturer's instruction. First, strand complementary DNA was synthesized using 2.0 mg of total RNA in a final volume of 20 ml and random primer. The complementary DNA was then amplified by PCR using 5 0 -ATGCTTCA TGCATCTTTTTCC-3 0 (forward) and 5 0 -TCACATAGA GCTAACAAAGTC-3 0 (reverse) primers for the HRPC gene detection.
Results
Adv-AFP-HRPC/IAA treatment increases cell death in hepatoma cells
We first evaluated the anti-tumor effect of Adv-AFP-HRPC/IAA system on HCC cell lines, Hep-3B, Hep-G2, Huh7 and H22 treated with IAA. IAA treatment-induced cell death in Adv-AFP-HRPC/IAA-infected cells was assessed using MTT assay. IAA-induced cell death in Adv-AFP-HRPC/IAA-infected cells was dose-dependent at 6 and 24 h after treatment (Figure 1a and b) . IAA at a concentration of 10 mg ml À1 induced majority of HCC cell death (Figure 1c Table 1 ). In addition, the weights of hepatoma xenografts in the mice treated with high dose (10 5 pfu) and middle dose (10 4 pfu) Adv-AFP-HRPC/IAA were decreased, compared with those in ADM-treated and control mice (Po0.05) (Figure 4b ). Furthermore, pathological examination showed that there was a large area of cell death in the section of tumor from the mice treated with Adv-AFP-HRPC/IAA (Figure 3) . No mouse treated 
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with Adv-AFP-HRPC/IAA died during the course of the study. In contrast, 20% mice treated with the vehicle and 13.3% ADM-treated mice died (Table 1) . Therefore, these results suggest that Adv-AFP-HRPC/IAA induces hepatoma cell death and reduce growth of hepatoma xenografts in mice.
No damage in normal organs in mice treated with Adv-AFP-HRPC/IAA Blood biochemical and hematological parameters of mice were evaluated. ADM-treated mice showed serious side effects, including decreasing white blood cells and increasing total bilirubin. Adv-AFP-HRPC/IAA-treated and control mice did not show any abnormal results in blood tests and liver function tests (Tables 2 and 3 ). The heart, liver, spleen, lung and kidneys were ablated and weighed. No change was found among these organs in treated groups, compared with control mice (Figure 4a ).
Expression of HRPC in the hepatoma xenografts
To determine whether Adv-AFP-HRPC/IAA treatment is specific for tumors, we examined the expression of HRPC gene in tumor tissues, brain, liver, spleen, lung and kidney using RT-PCR analysis. The results showed that HRPC gene expression was only found in tumor tissues of mice treated with Adv-AFP-HRPC/IAA, but not in the heart, liver, lung, kidney and brain of mice treated with Adv-AFP-HRPC/IAA ( Figure 5 ). 
Discussion
Currently, only surgery offers some clinical efficacy for HCC treatment. 24 Surgical resection provides a significant survival advantage for patients with early stage of HCC, however, many patients are diagnosed in the late stage and cannot tolerate hepatectomy because of poor liver function reserve. In addition, recurrence of HCC has been found in two-thirds of patients who undergo successful surgery, presumably from microscopic residual disease. For patients with unresectable liver metastases, palliative treatment, such as chemotherapy, yields clinical response in only one-third of cases. 26 Thus, alternative therapy is needed for both resectable and unresectable liver tumors.
HRP/IAA-mediated cancer therapy is a potential approach for cancer treatment with very low toxicity for normal tissue. Endogenous mammalian peroxidases are very inefficient in achieving comparable oxidative activation for IAA. When activated by exogenic HRP, it becomes a potent cytotoxin. If HRPC expression is specifically targeted in tumor cells, circulatory non-toxic IAA will be activated only in tumor cells, which can prevent cell damage in normal tissues. The human AFP promoter has been applied to direct the HCC-specific gene therapy for AFP-positive HCC. 27 AFP promoter can drive the desired gene expressing only in AFP-positive cells in HCC, but not in AFP-negative and low-AFPgenerating cells. 27, 28 In this study, we constructed Adv-AFP-HRPC system that can infect mammalian cells efficiently and selectively induce expression of HRPC proteins in hepatoma cells. IAA can be oxidized by HRPC to produce cytotoxin to induce tumor cell death. As mammalian peroxidases are not able to oxidize IAA, 26 we did not find any tissue damage in normal organs in mice with this treatment.
Our data are consistent with results reported before in other tumor types. Transfection of human bladder carcinoma T24 cells with HRPC gene 14 has shown reduced colony formation in the presence of IAA treatment compared with untransfected cells. Some of the early work with HRP/IAA combination demonstrated that HRP/IAA could induce apoptosis, which is one of the mechanisms for suppression of tumor growth. 19, 29 In this study, we explored the effects of Adv-AFP-HRPC/ IAA combination on inhibition of hepatoma growth using both in vitro and in vivo systems. Significant tumor growth inhibition (30.8 to 85.1%) was observed in the mice treated with HRPC/IAA, whereas tumor treated with vehicle was not affected. The inhibitory effects of Adv-AFP-HRPC/IAA treatment on hepatoma were due to its cytotoxicity to tumor cells. HRPC gene expression was confined only to tumor cells, but not to other organs, which eliminates side effects of HRPC/IAA therapy. Our studies further confirmed these results using blood biochemical and hematological assays, systemic necropsy and pathological section, which showed that no side effect was observed in Adv-AFP-HRPC/IAAtreated mice. Taken together, our results support the future clinical application of Adv-AFP-HRPC/IAA treatment for HCC.
